医学
遗传咨询
乳腺癌
随机对照试验
基因检测
干预(咨询)
苦恼
家庭医学
临床试验
癌症
物理疗法
护理部
临床心理学
内科学
遗传学
生物
作者
Kevin Sweet,Paul L. Reiter,Patrick Schnell,Leigha Senter,Kate Shane-Carson,Amber M. Aeilts,Julia Cooper,Christina Spears,Jordan Brown,Amanda E. Toland,Doreen M. Agnese,Mira L. Katz
标识
DOI:10.1016/j.cct.2023.107323
摘要
Genetic counseling and testing have an important role in the care of patients at elevated risk for breast cancer. However, conventional pre- and post-test genetic counseling is labor and time intensive, less accessible for patients living outside major urban centers, and impractical on a large scale. A patient-driven approach to genetic counseling and testing may increase access, improve patients' experiences, affect efficiency of clinical practice, and help meet workforce demand. The objective of this 2-arm randomized controlled trial is to determine the efficacy of Know Your Risk (KYR), a genetic counseling patient preference intervention. Females (n = 1000) at elevated risk (>20% lifetime) for breast cancer will be randomized to the KYR intervention or conventional genetic counseling. The study will provide comprehensive assessment of breast cancer risk by multigene panel testing and validated polygenic risk score. Primary outcome is adherence to National Comprehensive Cancer Network guidelines for a clinical encounter every 6–12 months and an annual mammogram (breast MRI if recommended) determined by medical record review. Secondary outcomes include adherence to other recommended cancer screening tests determined by medical record review and changes in breast cancer knowledge, perception of risk, post-test/counseling distress, and satisfaction with counseling by completion of three surveys during the study. Study aims will be evaluated for non-inferiority of the KYR intervention compared to conventional genetic counseling. If efficacious, the KYR intervention has the potential to improve patients' experience and may change how genetic counseling is delivered, inform best practices, and reduce workforce burden. Trial Registration: ClinicalTrials.gov NCT05325151
科研通智能强力驱动
Strongly Powered by AbleSci AI